Keep up to date with insights into hot topics and the biggest events
in the UC calendar
Dr Mark Samaan from Guy's and St Thomas' NHS Foundation Trust discusses how continued therapy with JYSELECA 200 mg is efficacious and well tolerated in patients with moderately to severely active ulcerative colitis.
Professor Iris Dotan and her multidisciplinary team explore the importance of a multidisciplinary approach to disease management.
Professor Séverine Vermeire and Kay Greveson examine the importance of alignment between the treatment goals of patients and healthcare professionals.
Professor Jimmy Limdi reviews the SELECTION Phase IIb/III clinical trial of filgotinib in patients with UC.
Dr Nick Powell dives into the role of the JAK-STAT pathway in inflammation.
Professor Jimmy Limdi reviews the latest evolutions in technology, with a focus on supporting patient-centric care.
Dr Nick Powell and Dr Rachel Cooney discuss the implementation of new treatment goals in order to improve patient outcomes in UC.
Dr Nick Powell and Dr Rachel Cooney discuss how to best support patients in aligning UC management with their treatment goals.
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos NV. JYSELECA is a registered or pending trademark of Gilead Sciences, Inc., or one of its related companies. © 2022 Galapagos NV. All rights reserved.
UK-IBD-FIL-202204-00018
Date of preparation May 2022
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos NV. JYSELECA is a registered or pending trademark of Gilead Sciences, Inc., or one of its related companies. © 2022 Galapagos NV. All rights reserved.
UK-IBD-FIL-202204-00018
Date of preparation May 2022
© 2022 Galapagos NV. All rights reserved.
You are about to leave this website and will be redirected to an external website. We are not responsible of that external website’s content. By continuing, you confirm that you have taken note of this.